Therapeutics

Aragen provides cell line development services for recombinant protein programmes using mammalian expression systems, including Chinese Hamster Ovary (CHO) cell platforms. Our capabilities support the development of recombinant proteins, including monoclonal antibodies and fusion proteins. Aragen’s cell line development platform includes its in-house CHO-DG44 platform, which may be used for recombinant protein production in cGMP manufacturing environments. We also utilise additional mammalian expression platforms, including CHO-S, CHO-GS and Sigma’s CHOZN platform.